Poster presentation at ESMO 2018 in Munich

October 23 | 2018

2cureX AB (“2cureX”) hereby announces that one of its clinical partners, Vejle Hospital presented a poster at the ESMO (European Society for Medical Oncology) congress in Munich 19-23 October 2018. The poster, which is called “Predictive value of in-vitro testing anti-cancer therapy sensitivity on 3D micro-tumors (tumoroids) from patients with metastatic colorectal cancer – a feasibility study”, contains information about the initial clinical feasibility study conducted in Q4 2017. 2cureX has previously presented clinical data from this ongoing clinical study in colorectal cancer at ESMO GI Barcelona in June 2018.

The poster was presented by Consultant, Associate Professor Lars Henrik Jensen (Department of Oncology, Vejle Hospital) and the title of the poster is Predictive value of in-vitro testing anti-cancer therapy sensitivity on 3D micro-tumors (tumoroids) from patients with metastatic colorectal cancer – a feasibility study. Abstract of the poster can be found here.

The conclusion of the presentation is: “This is the first clinical study of its kind. The method of selecting last-line treatment of colorectal cancer based on fresh biopsies was feasible as results were obtained in seven out of ten cases. The trial is now extended to a phase II trial with PFS as the primary endpoint”.

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer	Maarten van der Linden, Chief Business Officer
E-mail: ot@2curex.com	E-mail: ml@2curex.com
Phone: +45 221153 99	Phone: +45 22902469
www.2curex.com

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented and CE-IVD marked test for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal and ovarian cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).